Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Myriad Genetics (MYGN) Cash & Current Investments (2016 - 2026)

Myriad Genetics has reported Cash & Current Investments over the past 17 years, most recently at $149.6 million for Q4 2025.

  • Quarterly Cash & Current Investments rose 46.09% to $149.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $149.6 million through Dec 2025, up 46.09% year-over-year, with the annual reading at $149.6 million for FY2025, 46.09% up from the prior year.
  • Cash & Current Investments was $149.6 million for Q4 2025 at Myriad Genetics, up from $145.4 million in the prior quarter.
  • Over five years, Cash & Current Investments peaked at $366.1 million in Q3 2021 and troughed at $74.4 million in Q2 2025.
  • The 5-year median for Cash & Current Investments is $131.2 million (2023), against an average of $155.8 million.
  • Year-over-year, Cash & Current Investments skyrocketed 128.24% in 2021 and then tumbled 70.57% in 2023.
  • A 5-year view of Cash & Current Investments shows it stood at $338.8 million in 2021, then crashed by 66.09% to $114.9 million in 2022, then increased by 22.63% to $140.9 million in 2023, then fell by 27.32% to $102.4 million in 2024, then soared by 46.09% to $149.6 million in 2025.
  • Per Business Quant, the three most recent readings for MYGN's Cash & Current Investments are $149.6 million (Q4 2025), $145.4 million (Q3 2025), and $74.4 million (Q2 2025).